BRAF and neoplasm: ATA constantly refined its risk stratification models based on the latest research, as the ATA 2015-RSS were revised from its previous version in aspects including lymph nodes metastasis and BRAF mutation, etc. In clinical practice, our team found that previous studies of risk stratification models have ignored the effect of primary tumor location on recurrence in PTC patients.